FONAZINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H25N3O2S2.ClH
Molecular Weight	428.012
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)S(=O)(=O)N(C)C)N(C)C

InChI

InChIKey=YKXZRFSKLBBPQN-UHFFFAOYSA-N

InChI=1S/C19H25N3O2S2.ClH/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5;/h6-12,14H,13H2,1-5H3;1H

HIDE SMILES / InChI

Molecular Formula	C19H25N3O2S2
Molecular Weight	391.551
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.mufel.net/plm05/6816.htm
Curator's Comment: description was created based on several sources, including, https://www.jstage.jst.go.jp/article/gnam1977/3/2/3_113/_pdf, http://www.ncbi.nlm.nih.gov/pubmed/8564192

Fonzine (also known as dimetotiazine) is an analgesics and anti-inflammatory agent marketed in Japan and Europe under the name Migristene and indicated for the treatment of migraine and headaches secondary to other disease. Fonzine exerts its activity by inhibiting serotonin and histamine H1 receptors.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin (5-HT) receptor 34 Target ID: CHEMBL2096904 Sources: https://www.jstage.jst.go.jp/article/gnam1977/3/2/3_113/_pdf	Antagonist 2778
Histamine H1 receptor 315 Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/8564192	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 103 Sources: http://www.mufel.net/plm05/6816.htm	Primary		Approved 8429	MIGRISTENE Approved Use Prophylactic and curative treatment of migraine and headaches secondary other diseases.
Secondary headache 3 Sources: http://www.mufel.net/plm05/6816.htm	Primary		Approved 8429	MIGRISTENE Approved Use Prophylactic and curative treatment of migraine and headaches secondary other diseases.

PubMed

Title	Date	PubMed
[Resorption, excretion and biotransformation of 3-dimethylsulfamido-10-(2-dimethylaminopropyl)-phenothiazine (Dimetotiazine) in the rabbit and dog].	1967 Sep-Oct	5583624

Patents

Sample Use Guides

In Vivo Use Guide

Take 20-80 mg during the first day (2-4 tablets) and then - 40 mg/day (2 tablets) up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:19:16 GMT 2023` Edited by `admin` on `Sat Dec 16 08:19:16 GMT 2023`
Record UNII	X8U1M6U72V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FONAZINE HYDROCHLORIDE

Common Name

English

FONAZINE HYDROCHLORIDE [MI]

Common Name

English

DIMETHOTHIAZINE MONOHYDROCHLORIDE

Common Name

English

10H-PHENOTHIAZINE-2-SULFONAMIDE, 10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYL-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

ECHA (EC/EINECS)

251-996-0